RISK FACTORS FOR TUBERCULOSIS IN HIV INFECTED PATIENTS

March 1, 2014

Stoian Andreea Cristina 1, Niculescu Irina 1, Cupșa A. 1, Dumitrescu Florentina 1, Iocu Cristina 2, Giubelan L. 1, Marinescu Liliana 2
1 University of Medicine and Pharmacy from Craiova
2 “Victor Babes” Infectious Diseases Hospital from Craiova

Abstract

Objectives: To identify risk factors for tuberculosis (TB) in patients with HIV/AIDS (PIH), through a retrospective study. Methods: A retrospective study compared the period 01/01/2006- 31/12/2010 on two groups of PIH born between 1987-1990, horizontally infected with HIV in early childhood and ARV treatment: group A-16 PIH diagnosed with TB in 2010 and lot B-46 PIH without opportunistic infections at the time of inclusion in the lot (2010). Results: Demographics: group A-9M/7F; 7R/9U, median age = 20 years and group B-22M/24 F, 18 R/28U, median age = 21 years. Average BMI (kg/m²) in group A vs group B was: in T3-22.22 ± 4.18 vs 23.19 ± 3.99 (p=0.44) at T2-21.78±3.21 vs 22.43±3.78 (p=0,54) and T1-17,44±3,01 vs 22,11±4,18 (p=0.0001). Adherence of 95-100% (score 19-20) to ARV therapy was found in group A vs group B: the T3- 8 (53.33%) PIH vs 39 (84.78%) PIH (p=0.005; RR=3.29); the T2-7(43.75%) PIH vs 41 (89.13%) PIH ( p=0.0005; RR=5.18) and T1-9 (56.25%) PIH vs T3-44 (95.65%) PIH (p=0.001; RR=4.58). Average CD4 (cells/mm ³) in group A vs group B was: to the T3-331.09±182.54 vs 658.09±332.2 (p=0.0001), at T2-173±113.89 vs 616.3±377.16 (p=0.0004) and at T1- 103.82±53.21 vs 682.5±388.22 (p=0.0001). Average HIV-VL (copies/ml) in group A vs group B, was: to the T3-7893.23±2839.63 vs 2123.2±623.83 (p=0.0001), at T2-24790.25±7653.87 vs 954.71±224.33 (p=0.0001) and at T1-99520.97±24745.52 vs 78.43 ± 29.21 (p=0.0001). AIDS related clinical events were found in group A, 5 PIH (31.25%) and in group B, 2 PIH (4.34%) (p=0.03; RR=3.57). Conclusions: Identified risk factors for TB in PIH were downward evolutionary trend of CD4 cell count and upward of HIV-VL, within the 5 years before detection of these infections and AIDS related clinical events (nonTB), within 3 years before TB diagnosis, with poor adherence at ARV therapy.